



University of Kentucky
UKnowledge

Biology Faculty Publications

Biology

7-30-2013

Pharmacological Analysis of Dopamine Modulation in the *Drosophila melanogaster* Larval Heart

Josh S. Titlow

University of Kentucky, jstitlow@gmail.com

Jenna M. Rufer

Berea College

Kayla E. King

University of Kentucky, kayla.king@uky.edu

Robin L. Cooper

University of Kentucky, rlcoop1@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/biology_facpub

 Part of the [Biology Commons](#)

Repository Citation

Titlow, Josh S.; Rufer, Jenna M.; King, Kayla E.; and Cooper, Robin L., "Pharmacological Analysis of Dopamine Modulation in the *Drosophila melanogaster* Larval Heart" (2013). *Biology Faculty Publications*. 58.

https://uknowledge.uky.edu/biology_facpub/58

This Article is brought to you for free and open access by the Biology at UKnowledge. It has been accepted for inclusion in Biology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@sv.uky.edu.

Pharmacological Analysis of Dopamine Modulation in the *Drosophila melanogaster* Larval Heart

Notes/Citation Information

Published in *Physiological Reports*, v. 1, issue 2, e00020, p. 1-9.

© 2013 The Authors. *Physiological Reports* published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Digital Object Identifier (DOI)

<http://dx.doi.org/10.1002/phy2.20>

ORIGINAL RESEARCH

Pharmacological analysis of dopamine modulation in the *Drosophila melanogaster* larval heart

Josh S. Titlow¹, Jenna M. Rufer², Kayla E. King³ & Robin L. Cooper¹

¹ Department of Biology and Center for Muscle Biology, University of Kentucky, Lexington, KY, 40506-0225

² Department of Biology, Berea College, Berea, KY, 40403

³ Agricultural Biotechnology, University of Kentucky, Lexington, KY, 40506-0225

Keywords

Dopamine, *Drosophila melanogaster*, heart, larva, pharmacology.

Correspondence

Josh S. Titlow, Thomas Hunt Morgan Building
675 Rose Street, Lexington, KY 40506-0225.
Tel: (lab) 859-257-5950, (cell) 304-412-3497
Fax: 859-257-1717
E-mail: joshtitlow@uky.edu

Funding Information

Funding was provided by a G. Ribble Fellowship in the University of Kentucky Department of Biology (J. S. T.), a KBrIN summer research fellowship from the University of Kentucky (J. R.), and a summer research fellowship from the Outreach Center for Science and Health Career Opportunities at the University of Kentucky (K. E. K.).

Received: 26 April 2013; Revised: 23 May 2013; Accepted: 4 June 2013

doi: 10.1002/phy2.20

Physiol Rep, 1 (2), 2013, e00020, doi: 10.1002/phy2.20

Introduction

Dopamine (DA) is a well characterized neurotransmitter that also exhibits modulatory effects on peripheral tissues. Cardiac function is influenced by DA in several species, for example, *Periplaneta americana* (Collins and Miller 1977), *Ligia exotica* (Yamagishi et al. 2004b), *Tapes watlingi* (de Rome et al. 1980), *Drosophila melanogaster* (Zornik et al. 1999), *Canus lupus* (Chen et al. 2007), *Cavia porcellus* (Habuchi et al. 1997), *Mus musculus* (Asghar et al. 2011), and *Homo sapiens* (Cosyns et al. 2013). Chronic use of DA prodrugs (e.g., L-dopa) has

Abstract

Dopamine (DA) and other neurotransmitters affect nonneuronal tissues in insects by circulating in the hemolymph. In several organisms, DA has been shown to modulate distinct aspects of cardiac function but the signal transduction pathways that mediate dopaminergic effects on the heart are not well characterized. Here, we used a semiintact *Drosophila melanogaster* larva preparation and drugs targeting DA receptors and canonical second messenger pathways to identify signaling cascades that mediate the effect of DA on a myogenic heart. DA has a positive chronotropic effect that is mimicked by SKF38393 (type-1 DA receptor agonist) and quinpirole (type-2 DA receptor agonist). SCH23390 and spiperone (type-1 and type-2 DA receptor antagonists) are moderately effective at inhibiting DA's effect. An adenylate cyclase inhibitor (SQ,22536) is also effective at blocking the stimulatory effect of DA but the drug has its own dose-dependent effect. Activation of protein kinase C with a diacylglycerol analog has a stimulatory effect on heart rate (HR). These results suggest that (1) both DA receptor subtypes are expressed in third instar larva cardiac myocytes to increase HR in response to rising levels of DA in the hemolymph, and (2) canonical second messenger pathways modulate HR in *D. melanogaster* larvae. Having these disparate signaling cascades converge toward a common modulatory function appears redundant, but in the context of multiple cardioactive chemicals this redundancy is likely to increase the fidelity of signal transduction.

been linked to cardiac valve dysfunction in man (Delgado et al. 2012). Though DA receptors have been identified in mammalian cardiac tissue (Cavallotti et al. 2010; Tonnarini et al. 2011), pharmacological analysis of the effects of DA on heart rate (HR) and other aspects of cardiac function are lacking. Doing so will increase our understanding of how the cardiac rhythm is modulated and how it is affected by systemic DA homeostasis.

The larval *D. melanogaster* heart is a myogenic tube that spans the rostral:caudal axis of the animal (Gu and Singh 1995). Hemolymph is drawn into the heart through ostia in the posterior pump (which is analogous to a ventricle) and

circulated through an aorta back into the visceral lumen. Similarities in the developmental genetics (Bodmer 1995; Bodmer and Venkatesh 1998) and physiology (Choma et al. 2011) between *D. melanogaster* and human hearts make the larval heart an insightful model system.

DA has a positive chronotropic effect (meaning change in HR) on the adult and pupal heart (Johnson et al. 1997; Zornik et al. 1999). To investigate the molecular mechanisms mediating cardiac dopaminergic effects, we used the semi-intact *Drosophila* larva preparation (Cooper et al. 2009). One advantage of this preparation for pharmacological analysis is that the heart is quickly isolated from the nervous system and other sources of modulatory input. Because DA homeostasis is often manipulated systemically to study larval behavior (Neckameyer and Bhatt 2012) we are also interested in the effects of DA on cardiac function.

In the nervous system, and in smooth muscle, dopaminergic modulation proceeds through canonical G protein coupled receptor (GPCR) pathways (Neve et al. 2004). Arthropod DA receptors exhibit strong functional and pharmacological similarities to vertebrate receptors (Mustard et al. 2005; Yuan and Lee 2007). Four DA receptors have been described in *D. melanogaster*. Based on sequence identity and cAMP accumulation assays they can be classified as type-1 (DopR, DopR2, DopEcR) or type-2 (D2R) (Gotzes et al. 1994; Sugamori et al. 1995; Gotzes and Baumann 1996; Han et al. 1996). Type-1 DA and type-2 DA receptors are either positively or negatively coupled to adenylate cyclase through stimulatory and inhibitory G protein alpha subunits. Type-2 DA receptors are also known to function through protein kinase C (PKC) and calcium-dependent pathways (Yan et al. 1999). The degree to which GPCRs activate phospholipase-C and other second messenger cascades in *D. melanogaster* hearts is not completely understood and we are far from understanding how information from multiple signaling pathways is integrated. The aim of this study was to determine if vertebrate drugs targeting DA receptors and second messengers have an effect on this preparation with the long-term goal of dissecting interactions between multiple pathways.

Materials and Methods

HR assay

A Canton S. strain that has been isogenic in the lab for several years was used for all experiments. Flies were maintained on a 12 h light:dark cycle in bottles at medium density and fed standard cornmeal fly food (Bloomington stock center recipe). Early third instar larvae were pinned ventral side up on a glass plate and dissected in a

droplet of HL3 saline (Stewart et al. 1994): (in mmol/L) 70 NaCl, 5 KCl, 20 MgCl₂, 10 NaHCO₃, 1 CaCl₂, 5 trehalose, 115 sucrose, 25 N,N-Bis-(2-hydroxyethyl)-2-aminoethane sulfonic acid (BES). Note the following modifications: pH was decreased from 7.2 to 7.1 and BES buffer was increased from 5.0 mmol/L to 25.0 mmol/L to maintain stable pH. All recordings were made at room temperature (21–23°C) between 9 and 5 PM.

The larva dissection was first described by Gu and Singh (1995). Early third instars were opened by an incision in the ventral midline and visceral organs were removed without touching the heart. After recovering from surgery for 5 min the heart was visualized through a dissecting microscope and the baseline HR was measured by directly counting contractions in the posterior “heart” region. The saline was then carefully removed and exchanged with the various drug solutions. Counts in the new solution were taken 1 min after the exchange to allow the heart time to adjust after mechanical agitation, and for the ninth minute after applying the solution to determine the duration of modulatory effects. Hearts that did not beat continuously or stopped beating at the end of the experiment were not included in our analyses. As a control for the solution change, HR was measured after exchanging saline with fresh saline.

Pharmacology

SCH23390, SKF38393, Quinpirole, SQ22536, and phorbol-12-myristate-13-acetate (PMA) were purchased from Sigma Aldrich (St. Louis, MO). Spiperone was purchased from TOCRIS (Minneapolis, MN). DA HCl and each of the saline salts were purchased from Sigma. DA was weighed out and prepared daily. The other drugs were prepared from stock solutions. Lipophilic drugs were dissolved in saline solutions containing less than 1.0% dimethyl sulfoxide (DMSO). Saline containing 1.0% DMSO did not have an effect on larval HR.

Analysis

Heart rates were determined by counting the number of contractions observed in the posterior region of the heart (between seventh and eighth abdominal segments). Contractions were counted by visual inspection through a dissection microscope. The rates measured after drug treatment were normalized to the rate measured before drug treatment (baseline). Normalized values were then pooled for each treatment and the two-tailed Student's *t*-test (Sigma Plot, 12.0) was used to compare drug treatments to saline treatments (control) and to compare different concentrations of drug treatments. Data points depict the mean and SEM for each treatment at a given

1-min interval during the experiment. Sample sizes for each experiment are indicated in the figure legends.

Results

DA increases larval HR

The average baseline HR measured in dissected third instar larvae was 98.9 ± 2.5 beats per minute ($N = 164$). The distribution of baseline HRs in this preparation was skewed toward lower frequencies and the range exhibited threefold variation (Fig. 1A). Surgical and environmental differences explain a portion of this variation. Previous reports in nondissected flies show that up to 25% of the variation can be attributed to genotypic differences (Robbins et al. 1999). Statistical analyses were performed on baseline-normalized values to account for this variation.

On average $0.1 \mu\text{mol/L}$ DA increased HRs $36.02\% \pm 7.15\%$ above baseline (Fig. 1). At this concentration HR

increased in each individual experiment (Fig. 1B). DA caused a rapid rise in HR upon exposure and maintained a heightened level during the $0.1 \mu\text{mol/L}$ treatment (Fig. 1C). In most cases the increase persisted for at least 10 min and was not immediately washed out by saline after the treatment. The dose-response results (Fig. 1D) would suggest that $0.1 \mu\text{mol/L}$ DA reaches a saturation effect in increasing HR as higher concentrations did not produce significantly higher rates.

Type 1 and 2 DA receptors mediate dopaminergic modulation of larva HR

Pharmacological approaches were used to investigate the mechanisms of dopaminergic modulation in this system. Synthetic vertebrate DA receptor agonists and antagonists are known to bind to *Drosophila* DA receptors and have pharmacological effects comparable to vertebrates in heterologous expression systems (Gotzes et al. 1994). In




Figure 1. Dopamine (DA) has a positive chronotropic effect on larval heart rate (HR). (A) Baseline HR counts from all experiments, that is, 5 min after dissection and prior to application of drugs. (B) HR counts from seven individual experiments, before and 2 min after the saline was exchanged with $0.1 \mu\text{mol/L}$ DA. (C) Mean HR (normalized to baseline) plotted with time to show the full time course of the experiments ($n = 7$; $**P = 0.005$ and $*P = 0.03$ compared to saline changes, Student's t -test). The red bar depicts how long preparations were incubated in the drug solution. (D) Mean HR counts from the second and ninth minute of the experiment in response to different DA concentrations ($n > 7$ for each concentration; $*P < 0.05$ at 2nd minute, $+P < 0.05$ for the 9th minute compared to saline changes at those times, Student's t -test).

Drosophila cell culture (Yuan and Lee 2007) and in the intact nervous system (Yellman et al. 1997) several common vertebrate DA receptor drugs have been used to correlate specific DA receptors with a modulatory effect. The type-1 and type-2 DA receptor agonists used in these experiments were SKF38393 and quinpirole. SKF38393 was applied to larval hearts at 0.01, 0.1, and 10.0 $\mu\text{mol/L}$ concentrations. At each concentration there was an initial dose-dependent increase (20–70%) in HR followed by a return to rates that were 1–36% above baseline (Fig. 2A).

The type-2 agonist quinpirole caused an initial dose-dependent increase in HR that grew during the incubation to 12–53% above baseline (Fig. 2B). This was in contrast to the chronotropic effect of SKF38393, which diminished during the course of treatment ($P = 0.03$ at 10 $\mu\text{mol/L}$). Also the acute chronotropic effect of SKF38393 was smaller at higher concentrations. These




Figure 2. Synthetic vertebrate agonists for the two dopamine (DA) receptors increase HR in 3rd instar larvae. Agonist application regimens and HR counts were identical to DA experiments in Figure 1C, that is, change is shown relative to baseline 2 and 9 min after the drugs were applied. (A) SKF38393 (type-1 DA receptor agonist) and (B) quinpirole (type-2 DA receptor agonist) have positive chronotropic effects (** $P < 0.005$, * $P < 0.05$ compared to 2nd minute of saline treatment, Student's t -test, + $P < 0.05$ compared to 9th minute of saline treatment, Student's t -test; $N > 5$ different individuals for each treatment). The magnitude of the effects is statistically similar to DA but there are subtle differences in temporal and dose response. Efficacy of the type-1 DA receptor agonist decreased at higher concentrations.

results suggest that the type-1 DA receptors desensitize in response to prolonged exposure to ligand. Mechanisms of DA receptor desensitization have been described in neuronal tissues (Rex et al. 2008; Beaulieu and Gainetdinov 2011) but further pharmacological characterization is needed to confirm this phenomenon in *D. melanogaster* cardiac cells.

Antagonists for both DA receptor subtypes were moderately effective at blocking the effect of DA. For those experiments the dissected preparation was pretreated with either antagonist before adding a solution containing DA and the antagonist. HRs for the DA treatment were normalized to values recorded at the end of the pretreatment. The effect of DA (10 $\mu\text{mol/L}$) on HR was completely inhibited by antagonists for either DA receptor 9 min after DA was applied (Fig. 3A). The type-1 DA receptor antagonist (SCH23390, 10 $\mu\text{mol/L}$) significantly blocked the immediate effect of DA but the type-2 antagonist (spiperone, 10 $\mu\text{mol/L}$) was not as effective at this time point (i.e., 2 min after DA was applied). Spiperone initially increased HR during pretreatment but the rate returned to baseline levels before DA was added (Fig. 3B).




Figure 3. Type-1 and type-2 DAR antagonists partially block the modulatory effect of dopamine (DA) on larval HR. Dissected larva hearts were pretreated with a DA receptor antagonist for 10 min prior to DA application. The dopaminergic increase in HR was partially blocked by either drug 2 min after DA application, and almost completely blocked 9 min after DA application (* $P < 0.05$ compared to the effect of DA without the antagonist at that time point, Student's t -test, $n > 8$ different individuals for each treatment). SCH23390 is a type-1 DA receptor antagonist (gray data points) and spiperone is a type-2 DA receptor antagonist (black data points). The dopaminergic effect without pretreatment with antagonists is shown in light red. (B) SCH23390 alone did not have an effect on HR at either time point. Spiperone caused a slight but significant increase in HR that diminished before DA was added.

Possible explanations for this result are that the drug has off-target effects or that the drug inhibited the function of a constitutively active DA receptor. Constitutively active DA receptors have been identified in *Aplysia* heart (Barbas et al. 2006) and in mammalian nervous system (Tiberi and Caron 1994; Charpentier et al. 1996).

Adenylate cyclase and PKC are involved in modulation of HR

To determine if DA acts on the heart through classical stimulatory GPCR pathways, the vertebrate adenylate cyclase inhibitor SQ22536 (SQ) was tested in the same manner as the DA receptor antagonists, that is, the drug was applied for 10 min before applying it in solution with 10 $\mu\text{mol/L}$ DA. HRs were measured at the end of this treatment and later time points were normalized to those pretreatment rates. Under these conditions the modulatory effect of DA (10 $\mu\text{mol/L}$) was significantly inhibited by 5 $\mu\text{mol/L}$ SQ (Fig. 4A). Oddly SQ was less effective at 500 $\mu\text{mol/L}$ and at both concentrations SQ alone had a stimulatory effect on HR (Fig. 4B). Though the drug clearly inhibits dopaminergic modulation in this context, we are unable to rule out the possibility of off-target mechanisms.




Figure 4. Dopaminergic modulation of larval HR is mediated by adenylate cyclase. Dissected hearts were pretreated for 10 min with SQ22536 (adenylate cyclase inhibitor) as in Figure 3. HRs shown here were normalized to the rate recorded at the end of SQ22536 treatment. (A) At 500 $\mu\text{mol/L}$ (black data points) and at 5 $\mu\text{mol/L}$ (gray data points) the drug attenuated the effect of dopamine (DA). Inhibition was only statistically significant for the lower concentration ($*P < 0.05$ compared to DA alone (shown in light red), Student's t -test; $n > 9$ individuals for each concentration). (B) At both concentrations SQ22536 alone increased HR relative to saline treatment ($*P < 0.05$, Student's t -test, pretreatment rates from preparations in [A]).

The diacylglycerol (DAG) analog PMA was used to determine if PKC is involved in modulation of larval HR. This drug consistently increased HR and was more effective at 100 $\mu\text{mol/L}$ than at 10 $\mu\text{mol/L}$ (Fig. 5). At both concentrations the effect lasted for 10 min and was not immediately washed out.

Calcium ion reduction inhibits dopaminergic modulation of larval HR

To test the hypothesis that Ca^{2+} influx is a factor in dopaminergic modulation of larval HR, we experimented with various levels of $[\text{Ca}^{2+}]_o$. The normal HL3 saline contains 1.0 mm CaCl_2 (Stewart et al. 1994). At 0.1 mm Ca^{2+} the hearts did not beat, but changing the saline to 0.5 mm Ca^{2+} revived them from cardiac arrest ($n = 5$). In this low calcium solution DA (10 $\mu\text{mol/L}$) did not have an effect on HR (Fig. 6). High calcium saline (2.0 mm) did not change the effect of DA at any point. Therefore, calcium influx is necessary for dopaminergic modulation of HR and it appears that $[\text{Ca}^{2+}]_o$ contributes its maximum input at 1 mmol/L. Higher $[\text{Ca}^{2+}]_o$ is known to substantially increase HR and further modulatory effects are difficult to ascertain at higher frequencies (Desai-Shah et al. 2010). After washing away DA in the low calcium solution there was a 40% increase in HR. Slight increases after washout were observed in other treatments (Figs. 1C and 3) but this phenomenon was accentuated in this condition. One explanation is that after several minutes without calcium the tissue developed an increased sensitivity to mechanical stress, causing an elevated response to the solution change.




Figure 5. Activation of protein kinase C (PKC) has a positive chronotropic effect on HR. Phorbol-myristate-acetate (PMA), a cell permeable diacylglycerol analog, was used to determine if PKC acts as a second messenger in modulation of insect HR. The stimulatory effect of PMA was much stronger at the higher concentration ($*P < 0.005$ after 2nd minute compared to 10 $\mu\text{mol/L}$, $+P < 0.005$ after the 9th minute compared to 10 $\mu\text{mol/L}$; $n > 10$ different animals for both concentrations).




Figure 6. The modulatory effect of dopamine (DA) on heart rate (HR) is correlated with extracellular Ca^{2+} levels. 1.0 mmol/L (red data points) is the normal $[\text{Ca}^{2+}]$ used for HL3 (hemolymph-like) fly saline. In low $[\text{Ca}^{2+}]$ conditions (gray data points) the positive chronotropic effect of DA was not observed. In high calcium (black data points) the effect of DA is unaffected, though the persistence of the dopaminergic effect is slightly stronger in this condition. Data points with different letters exhibited significantly different rates ($P < 0.05$, Student's t -test; $n > 6$ for each $[\text{Ca}^{2+}]$ tested). The solution used for dissection contained the same $[\text{Ca}^{2+}]$ as the treatment solution.

Discussion

Positive chronotropic effect of DA on *D. melanogaster* larval hearts

Endogenous DA levels fluctuate in response to environmental cues and an animal's state of arousal (Noguchi et al. 1995). In insects DA modulates peripheral organs by circulating in hemolymph at concentrations in the micromolar range (Matsumoto et al. 2003). The source of hemolymph DA is debatable but it likely originates from hypodermal cells that secrete DA to harden the cuticle (Wright 1987; Friggi-Grelín et al. 2003) or from neurohemal axon terminals (Buma 1988) and varicose projections within the nervous system (Helle et al. 1995), as is the case in other invertebrates. Regardless of the source, our data show how a sudden increase in DA has a positive chronotropic effect on the semi-intact larval heart in *D. melanogaster*. This effect has not been described in larvae but Zornik et al. (1999) reported a positive chronotropic effect in adults and a negative effect in pupae. Two factors that may have led to different findings between the two studies were the developmental stage and genotype. Here, early third instar larvae from the Canton S line were used whereas the previous study used Oregon R flies in the "wandering" third instar stage. Using intact P1 pupal stage from the Canton S line, Johnson et al. (1997) observed that DA has a positive chronotropic effect. Similar developmentally specific dopaminergic effects on HR have also been reported in the sea roach, *L. exotica* (Yamagishi et al. 2004a). Moreover DA has a positive

chronotropic effect on the cockroach heart (Collins and Miller 1977). The data suggest that DA is regulating HR by modulating pacemaker activity in cardiac myocytes (Johnson et al. 2002), but whether modulation occurs directly in the myocardial cell layer or indirectly through the epicardium is unclear (Su et al. 1999). We did not measure contractile force generated by the cardiac tube but experiments in *Limulus polyphemus* have shown that DA can have a positive inotropic effect (change in contractile function) on invertebrate heart muscle and that the effect is mediated by cyclic-AMP and PKC (Groome and Watson 1989).

Canonical second messenger pathways involved in fruit fly HR modulation

Using SQ and ion substitution we showed that DA exerts its positive chronotropic effect on HR through adenylate cyclase and calcium influx (Figs. 4 and 6). Coupling of a *D. melanogaster* type-1 DA receptor to increases in intracellular Ca^{2+} and cyclic-AMP through G proteins has been demonstrated in *Xenopus* oocytes (Reale et al. 1997). The effect of cyclic-AMP is subtle and confounded by the fact that SQ increased HR. In pupal hearts a cyclic-AMP analog (8-bromo-cAMP) had a very small stimulatory effect (9.5%) and forskolin did not significantly affect HR (Johnson et al. 2002). Mutations in adenylate cyclase (*rutabaga*) and cAMP phosphodiesterase (*dunce*) did not significantly alter the stimulatory effects of cardioactive molecules (Johnson et al. 2002). However, there is strong genetic evidence that indicates the involvement of calcium and phospholipase C in modulation of HR (Johnson et al. 2002) and our pharmacological data are consistent with those findings.

We showed that direct activation of PKC has a dose-dependent stimulatory effect on larval HR (Fig. 5). The PKC pathway could modulate HR by targeting calcium channels. In rat ventricular myocytes an L-type calcium current is modulated through a PKC-dependent pathway (Chen et al. 2012). Calcium handling in *Drosophila* myocytes exhibits many of the same physiological properties observed in mammalian myocytes. L-type Ca^{2+} channels enable periodic waves of calcium influx (Gu and Singh 1995). Intracellular calcium is in turn buffered by sarcoplasmic/endoplasmic reticulum Ca^{2+} -ATPase (Sanyal et al. 2006) and a sodium/calcium exchanger (Desai-Shah et al. 2010). Larval HR is positively correlated with extracellular calcium, for example, decreasing $[\text{Ca}^{2+}]_o$ from 1.0 mmol/L to 0.5 mM decreases HR by over 50%, and increasing $[\text{Ca}^{2+}]_o$ from 1.0 to 2.0 mmol/L increases HR by 40% (Desai-Shah et al. 2010). Although the experiments reported here did not directly address activation of PKC signaling by DA, evidence from rat myocytes

(Li et al. 2009) and *Aplysia* sensory neurons (Dunn et al. 2012) indicate that DA modulates the function of those cells through a PKC-dependent pathway.

Though DA and the DA receptor agonists used here were effective at doses that are likely below the threshold to exert off-target effects, our experiments do not completely rule out the possibility that DA was acting through an adrenergic or other aminergic receptor. Norepinephrine and an alpha-adrenergic receptor agonist have been shown to increase pupal HR in *D. melanogaster* (Johnson et al. 2002). However, there are no true adrenergic receptors in *D. melanogaster* (Evans and Maqueira 2005). These molecules are believed to act through octopamine or tyramine receptors, which exhibit pharmacological properties similar to adrenergic receptors (Bayliss et al. 2013).

Future studies and impact

In *D. melanogaster* a leak current from an outward rectifying potassium channel (ORK1) regulates HR by controlling membrane excitability and in turn the slow diastolic depolarization phase (Lalevee et al. 2006). It is possible that DA influences HR through protein kinases that inactivate ORK1 through phosphorylation. Indeed it was shown that HR increased when expression of this channel was knocked down (Lalevee et al. 2006). The current work establishes a system for addressing hypotheses about the mechanisms of aminergic modulation of the heart using electrophysiological techniques and transgenic flies.

In mammals the effects of DA on cardiovascular function have been studied extensively. Chronotropic, ionotropic, and pressor effects have been demonstrated in guinea pigs, rabbits, dogs, and in humans (Tsai et al. 1967; Wakita 2007). In several instances the results are contradictory and complicated by the fact that DA acts on smooth muscle as a vasodilator, it modulates parasympathetic innervations to the heart, and can be taken up by neurons and converted to norepinephrine. Nonetheless it has been shown that each DA receptor subtype is expressed in mammalian hearts (Cavallotti et al. 2010; Tonnarini et al. 2011), giving some support to the idea that DA or DA receptor agonists could modulate the mammalian heart directly. A current concern is that extended use of DA prodrugs (e.g., L-dopa) and DA receptor agonists for neurobiological disorders has been associated with cardiac valve dysfunction (Delgado et al. 2012; Trifiro et al. 2012). Though circulating DA levels are typically not high enough to activate DA receptors (Zeng and Jose 2011), these pharmacological agents seem to influence cardiac function through DA pathways. The larval heart has a pair of intracardiac cells that function as a valve (Zeitouni et al. 2007; Lehmacher et al. 2012), so this system could potentially be used to address the

molecular mechanisms that cause this valvular dysfunction associated with DA treatments.

Conclusion

Our pharmacological analysis indicates that the chronotropic effect of DA is mediated by functionally conserved G protein coupled DA receptors and canonical second messenger pathways. The results also indicate that calcium flux is an important element of dopaminergic modulation in the heart. These data can guide future studies that address interactions between signaling pathways and homeostatic changes to monoamine signaling using the genetic tools available in this system.

Acknowledgments

Funding was provided by a G. Ribble Fellowship in the University of Kentucky Department of Biology (J. S. T.), a KBrIN summer research fellowship from the University of Kentucky (J. R.), and a summer research fellowship from the Outreach Center for Science and Health Career Opportunities at the University of Kentucky (K. E. K.). Personal funds were also used to support this project (R. L. C.).

Conflict of Interest

None declared.

References

- Asghar, M., S. K. Tayebati, M. F. Lokhandwala, and T. Hussain. 2011. Potential dopamine-1 receptor stimulation in hypertension management. *Curr. Hypertens. Rep.* 13:294–302.
- Barbas, D., J. P. Zappulla, S. Angers, M. Bouvier, H. A. Mohamed, J. H. Byrne, et al. 2006. An *Aplysia* dopamine1-like receptor: molecular and functional characterization. *J. Neurochem.* 96:414–427.
- Bayliss, A., G. Roselli, and P. D. Evans. 2013. A comparison of the signalling properties of two tyramine receptors from *Drosophila*. *J. Neurochem.* 125:37–48.
- Beaulieu, J. M., and R. R. Gainetdinov. 2011. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol. Rev.* 63:182–217.
- Bodmer, R. 1995. Heart development in *Drosophila* and its relationship to vertebrates. *Trends Cardiovasc. Med.* 5: 21–28.
- Bodmer, R., and T. V. Venkatesh. 1998. Heart development in *Drosophila* and vertebrates: conservation of molecular mechanisms. *Dev. Genet.* 22:181–186.
- Buma, P. 1988. Synaptic and nonsynaptic release of neuromediators in the central nervous system. *Acta Morphol. Neerl. Scand.* 26:81–113.

- Cavallotti, C., M. Mancone, P. Bruzzone, M. Sabbatini, and F. Mignini. 2010. Dopamine receptor subtypes in the native human heart. *Heart Vessels* 25:432–437.
- Charpentier, S., K. R. Jarvie, D. M. Severynse, M. G. Caron, and M. Tiberi. 1996. Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties. *J. Biol. Chem.* 271:28071–28076.
- Chen, H. C., M. D. Sinclair, and D. H. Dyson. 2007. Use of ephedrine and dopamine in dogs for the management of hypotension in routine clinical cases under isoflurane anesthesia. *Vet. Anaesth. Analg.* 34:301–311.
- Chen, R. X., F. Liu, Y. Li, and G. A. Liu. 2012. Neuromedin S increases L-type Ca^{2+} channel currents through G(i) α -protein and phospholipase C-dependent novel protein kinase C delta pathway in adult rat ventricular myocytes. *Cell. Physiol. Biochem.* 30:618–630.
- Choma, M. A., M. J. Suter, B. J. Vakoc, B. E. Bouma, and G. J. Tearney. 2011. Physiological homology between *Drosophila melanogaster* and vertebrate cardiovascular systems. *Dis. Model. Mech.* 4:411–420.
- Collins, C., and T. Miller. 1977. Studies on the action of biogenic amines on cockroach heart. *J. Exp. Biol.* 67:1–15.
- Cooper, A. S., K. E. Rymond, M. A. Ward, E. L. Bocook, and R. L. Cooper. 2009. Monitoring heart function in larval *Drosophila melanogaster* for physiological studies. *J. Vis. Exp.* e1596, doi:10.3791/1596.
- Cosyns, B., S. Droogmans, R. Rosenhek, and P. Lancellotti. 2013. Drug-induced valvular heart disease. *Heart* 99:7–12.
- Delgado, V., N. R. Biermasz, S. W. van Thiel, S. H. Ewe, N. A. Marsan, E. R. Holman, et al. 2012. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. *Clin. Endocrinol.* 77:99–105.
- Desai-Shah, M., A. R. Papoy, M. Ward, and R. L. Cooper. 2010. Roles of the Sarcoplasmic/Endoplasmic reticulum Ca^{2+} -ATPase, plasma membrane Ca^{2+} -ATPase and $\text{Na}^{+}/\text{Ca}^{2+}$ exchanger in regulation of heart rate in larval *Drosophila*. *Open Physiol. J.* 3:16–36.
- Dunn, T. W., C. A. Farah, and W. S. Sossin. 2012. Inhibitory responses in Aplysia pleural sensory neurons act to block excitability, transmitter release, and PKC Apl II activation. *J. Neurophysiol.* 107:292–305.
- Evans, P. D., and B. Maqueira. 2005. Insect octopamine receptors: a new classification scheme based on studies of cloned *Drosophila* G-protein coupled receptors. *Invert. Neurosci.* 5:111–118.
- Friggi-Grelín, F., M. Iche, and S. Birman. 2003. Tissue-specific developmental requirements of *Drosophila* tyrosine hydroxylase isoforms. *Genesis* 35:260–269.
- Gotzes, F., and A. Baumann. 1996. Functional properties of *Drosophila* dopamine D1-receptors are not altered by the size of the N-terminus. *Biochem. Biophys. Res. Commun.* 222:121–126.
- Gotzes, F., S. Balfanz, and A. Baumann. 1994. Primary structure and functional characterization of a *Drosophila* dopamine receptor with high homology to human D1/5 receptors. *Receptors Channels* 2:131–141.
- Groome, J. R., and W. H. 3rd Watson. 1989. Second-messenger systems underlying amine and peptide actions on cardiac muscle in the horseshoe crab *Limulus polyphemus*. *J. Exp. Biol.* 145:419–437.
- Gu, G. G., and S. Singh. 1995. Pharmacological analysis of heartbeat in *Drosophila*. *J. Neurobiol.* 28:269–280.
- Habuchi, Y., H. Tanaka, M. Nishio, T. Yamamoto, T. Komori, J. Morikawa, et al. 1997. Dopamine stimulation of cardiac beta-adrenoceptors: the involvement of sympathetic amine transporters and the effect of SKF38393. *Br. J. Pharmacol.* 122:1669–1678.
- Han, K. A., N. S. Millar, M. S. Grotewiel, and R. L. Davis. 1996. DAMB, a novel dopamine receptor expressed specifically in *Drosophila* mushroom bodies. *Neuron* 16:1127–1135.
- Helle, J., H. Dirksen, M. Eckert, D. R. Nassel, U. Sporhase-Eichmann, and F. W. Schurmann. 1995. Putative neurohemal areas in the peripheral nervous system of an insect, *Gryllus bimaculatus*, revealed by immunocytochemistry. *Cell Tissue Res.* 281:43–61.
- Johnson, E., J. Ringo, and H. Dowse. 1997. Modulation of *Drosophila* heartbeat by neurotransmitters. *J. Comp. Physiol. B, Biochem. Syst. Environ. Physiol.* 167:89–97.
- Johnson, E., T. Sherry, J. Ringo, and H. Dowse. 2002. Modulation of the cardiac pacemaker of *Drosophila*: cellular mechanisms. *J. Comp. Physiol. B, Biochem. Syst. Environ. Physiol.* 172:227–236.
- Lalevee, N., B. Monier, S. Senatore, L. Perrin, and M. Semeriva. 2006. Control of cardiac rhythm by ORK1, a *Drosophila* two-pore domain potassium channel. *Curr. Biol.* 16:1502–1508.
- Lehmacher, C., B. Abeln, and A. Paululat. 2012. The ultrastructure of *Drosophila* heart cells. *Arthropod. Struct. Dev.* 41:459–474.
- Li, H., S. Shi, Y. H. Sun, Y. J. Zhao, Q. F. Li, H. Z. Li, et al. 2009. Dopamine D2 receptor stimulation inhibits angiotensin II-induced hypertrophy in cultured neonatal rat ventricular myocytes. *Clin. Exp. Pharmacol. Physiol.* 36:312–318.
- Matsumoto, H., K. Tanaka, H. Noguchi, and Y. Hayakawa. 2003. Cause of mortality in insects under severe stress. *Eur. J. Biochem.* 270:3469–3476.
- Mustard, J. A., K. T. Beggs, and A. R. Mercer. 2005. Molecular biology of the invertebrate dopamine receptors. *Arch. Insect Biochem. Physiol.* 59:103–117.
- Neckameyer, W. S., and P. Bhatt. 2012. Neurotrophic actions of dopamine on the development of a serotonergic feeding circuit in *Drosophila melanogaster*. *BMC Neurosci.* 13:26.
- Neve, K. A., J. K. Seamans, and H. Trantham-Davidson. 2004. Dopamine receptor signaling. *J. Recept. Signal Transduct. Res.* 24:165–205.

- Noguchi, H., Y. Hayakawa, and R. G. H. Downer. 1995. Elevation of dopamine levels in parasitized insect larvae. *Insect Biochem. Mol. Biol.* 25:197–201.
- Reale, V., F. Hannan, L. M. Hall, and P. D. Evans. 1997. Agonist-specific coupling of a cloned *Drosophila melanogaster* D1-like dopamine receptor to multiple second messenger pathways by synthetic agonists. *J. Neurosci.* 17:6545–6553.
- Rex, E. B., M. L. Rankin, M. A. Ariano, and D. R. Sibley. 2008. Ethanol regulation of D(1) dopamine receptor signaling is mediated by protein kinase C in an isozyme-specific manner. *Neuropsychopharmacology* 33:2900–2911.
- Robbins, J., R. Aggarwal, R. Nichols, and G. Gibson. 1999. Genetic variation affecting heart rate in *Drosophila melanogaster*. *Genet. Res.* 74:121–128.
- de Rome, P. J., D. D. Jamieson, K. M. Taylor, and L. P. Davies. 1980. Ligand-binding and pharmacological studies on dopamine and octopamine receptors in the heart of the bivalve mollusc, *Tapes watlingi*. *Comp. Biochem. Physiol. C* 67C:9–16.
- Sanyal, S., T. Jennings, H. Dowse, and M. Ramaswami. 2006. Conditional mutations in SERCA, the Sarco-endoplasmic reticulum Ca²⁺ -ATPase, alter heart rate and rhythmicity in *Drosophila*. *J. Comp. Physiol. B, Biochem. Syst. Environ. Physiol.* 176:253–263.
- Stewart, B. A., H. L. Atwood, J. J. Renger, J. Wang, and C. F. Wu. 1994. Improved stability of *Drosophila* larval neuromuscular preparations in haemolymph-like physiological solutions. *J. Comp. Physiol. A.* 175:179–191.
- Su, M. T., T. V. Venkatesh, X. Wu, K. Golden, and R. Bodmer. 1999. The pioneer gene, *apontic*, is required for morphogenesis and function of the *Drosophila* heart. *Mech. Dev.* 80:125–132.
- Sugamori, K. S., L. L. Demchyshyn, F. McConkey, M. A. Forte, and H. B. Niznik. 1995. A primordial dopamine D1-like adenylyl cyclase-linked receptor from *Drosophila melanogaster* displaying poor affinity for benzazepines. *FEBS Lett.* 362:131–138.
- Tiberi, M., and M. G. Caron. 1994. High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. *J. Biol. Chem.* 269:27925–27931.
- Tonnarini, G., C. Parlapiano, D. Cavallotti, A. Tego, M. Curione, G. Giancaspro, et al. 2011. Dopamine receptor subtypes in the human coronary vessels of healthy subjects. *J. Recept. Signal Transduct. Res.* 31:33–38.
- Trifiro, G., M. M. Mokhles, J. P. Dieleman, E. M. van Soest, K. Verhamme, G. Mazzaglia, et al. 2012. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. *Drug Saf.* 35:159–171.
- Tsai, T. H., S. Z. Langer, and U. Trendelenburg. 1967. Effects of dopamine and alpha-methyl-dopamine on smooth muscle and on the cardiac pacemaker. *J. Pharmacol. Exp. Ther.* 156:310–324.
- Wakita, Y. 2007. Inotropic, chronotropic, and arrhythmogenic effects of dopamine on the isolated working heart of rabbit. *J. Physiol. Sci.* 57:147–157.
- Wright, T. R. 1987. The genetics of biogenic amine metabolism, sclerotization, and melanization in *Drosophila melanogaster*. *Adv. Genet.* 24:127–222.
- Yamagishi, H., H. Miyamoto, and A. Sakurai. 2004a. Developmental changes in dopamine modulation of the heart in the isopod crustacean *Ligia exotica*: reversal of chronotropic effect. *Zoolog. Sci.* 21:917–922.
- Yamagishi, H., S. Takano, and K. Tanaka. 2004b. Dual effects of dopamine on the adult heart of the isopod crustacean *Ligia exotica*. *Zoolog. Sci.* 21:15–21.
- Yan, Z., J. Feng, A. A. Fienberg, and P. Greengard. 1999. D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. *Proc. Natl. Acad. Sci. USA* 96:11607–11612.
- Yellman, C., H. Tao, B. He, and J. Hirsh. 1997. Conserved and sexually dimorphic behavioral responses to biogenic amines in decapitated *Drosophila*. *Proc. Natl. Acad. Sci. USA* 94:4131–4136.
- Yuan, N., and D. Lee. 2007. Suppression of excitatory cholinergic synaptic transmission by *Drosophila* dopamine D1-like receptors. *Eur. J. Neurosci.* 26:2417–2427.
- Zeitouni, B., S. Senatore, D. Severac, C. Aknin, M. Semeriva, and L. Perrin. 2007. Signalling pathways involved in adult heart formation revealed by gene expression profiling in *Drosophila*. *PLoS Genet.* 3:1907–1921.
- Zeng, C., and P. A. Jose. 2011. Dopamine receptors: important antihypertensive counterbalance against hypertensive factors. *Hypertension* 57:11–17.
- Zornik, E., K. Paisley, and R. Nichols. 1999. Neural transmitters and a peptide modulate *Drosophila* heart rate. *Peptides* 20:45–51.